Mei Mei Hu, J.D. leads a company with some lofty ambitions. The democratization of healthcare, interplanetary colonization, and development of accessible therapeutic vaccines to serve and enable both. Those big-picture visions have helped the company establish itself as a pioneer of the "third biologics revolution." On Business of Biotech podcast, the CEO shares Vaxxinity's strategy, what "democratization" and "revolution" really mean and a whole lot more. Listen now.
Article |
By Dr. Svea Grieb, Kai Touw, and Dan Kopec,Sartorius
Industry experts for process analytical technologies, automation, and data analytics share their views on the implications of the Internet of Things and robotics on the future of bioprocessing.
For peptide APIs, using a liquid phase peptide synthesis (LPPS) approach offers a cost-effective process for large-scale manufacture by eliminating the need for specialized equipment and excess raw materials.
Early planning for scale-up and biologics license application activities can maximize your chances of success by allowing sufficient time to develop launch options and prevent costly delays and setbacks.
We give an overview on the theory of scaling, present workflows and strategies, discuss which data are needed for successful scaling, and present case studies that use a web-based scaling tool
Growing complexity and risks in drug development and supply have implications for outsourcing models. See how to structure and manage CDMO partnerships for a future with uncertainty and disruption.
Late-phase development requires a holistic development strategy driven by a well-defined target product profile. This webinar aims to provide you with an overview of the complex path to a successful product launch.
